Kenvue Inc. (NYSE:KVUE) Shares Sold by KBC Group NV

KBC Group NV lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 44.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 533,666 shares of the company’s stock after selling 432,494 shares during the quarter. KBC Group NV’s holdings in Kenvue were worth $11,394,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Public Sector Pension Investment Board lifted its stake in shares of Kenvue by 92.9% in the second quarter. Public Sector Pension Investment Board now owns 73,637 shares of the company’s stock valued at $1,339,000 after purchasing an additional 35,461 shares during the period. Creative Planning grew its holdings in shares of Kenvue by 15.4% in the 2nd quarter. Creative Planning now owns 379,045 shares of the company’s stock worth $6,891,000 after acquiring an additional 50,562 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in Kenvue by 13.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 62,687 shares of the company’s stock valued at $1,140,000 after purchasing an additional 7,564 shares in the last quarter. Sunbelt Securities Inc. raised its stake in shares of Kenvue by 28.3% during the 2nd quarter. Sunbelt Securities Inc. now owns 28,766 shares of the company’s stock worth $523,000 after buying an additional 6,353 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. raised its position in Kenvue by 7.2% during the second quarter. B. Riley Wealth Advisors Inc. now owns 27,278 shares of the company’s stock worth $496,000 after acquiring an additional 1,838 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $21.35 on Thursday. The business’s fifty day moving average price is $22.05 and its 200 day moving average price is $21.85. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $40.92 billion, a P/E ratio of 38.81, a PEG ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.31 EPS. As a group, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.84%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group reduced their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday, January 16th. JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Finally, Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.